On February 4, 2026, GlaxoSmithKline (GSK), a global leader in healthcare, announced its performance for the fourth quarter and full year of 2025. The report highlights GSK's strong performance in a complex market environment: the company's total revenue for the year reached ￡32.67 billion (approximately $42.8 billion), marking a 4% increase compared to 2024 (at actual exchange rates, AER), or a 7% increase at constant exchange rates (CER). Core operating profit stood at ￡9.78 billion, up by 7% (AER) or 11% (CER). The fourth-quarter performance was particularly impressive, with revenue increasing by 6% (AER) to ￡8.62 billion, showcasing the company's strong position in specialty medicines and vaccines. This article, based on GSK's official announcement, provides an in-depth analysis of its 2025 performance, examining financial results, business division performance, regional markets, research and development (R&D) innovations, legal risks, and future outlook.
In 2025, GSK achieved comprehensive financial growth. The total revenue for the year amounted to ￡32.67 billion, a 4% increase from ￡31.38 billion in 2024 (AER). When excluding the impact of exchange rate fluctuations (CER), the growth was even more pronounced, at 7%. This growth was driven primarily by the strong demand for specialty medicines and vaccines, which partly offset the decline in general medicines. Core operating profit reached ￡9.78 billion, a 7% increase (AER), with the core operating margin rising to 29.9%, reflecting GSK's efforts to optimize its product portfolio and control costs. Core earnings per share (EPS) grew by 8%, highlighting the improvement in shareholder value.
The fourth-quarter performance was particularly strong, with revenue increasing by 6% (AER) to ￡8.62 billion and core operating profit rising by 14% to ￡1.63 billion. This was driven by the launch of new products and seasonal factors, such as the contribution of the respiratory syncytial virus (RSV) vaccine, Arexvy.
Regarding cash flow, GSK reported operating cash flow of ￡7.74 billion and free cash flow of ￡4.03 billion, a significant improvement from ￡2.86 billion in 2024, reflecting strong working capital management. Net debt increased to ￡14.45 billion from ￡13.09 billion in 2024, primarily due to business acquisitions and shareholder returns. However, the net debt-to-core EBITDA ratio remained at a healthy level of 1.3x. Overall, GSK's financial foundation remains solid, with growth in both quantity and quality, laying the groundwork for future investment.
GSK's business is divided into three main segments: specialty medicines, vaccines, and general medicines. In 2025, the company saw differentiated growth across these segments. Specialty medicines revenue grew by 12% (CER) to ￡17.90 billion, becoming the largest growth driver. Key contributors included HIV medications, such as the long-acting injectable regimen Cabenuva and the oral medication Dovato, which contributed to a 10% revenue increase. Oncology products like Jemperli and Blenrep showed significant contributions through expanded indications. In respiratory and immunology, Nucala grew by 9%, driven by new indications like chronic obstructive pulmonary disease (COPD), and the newly launched ultra-long-acting drug Exdensur (depemokimab) also showed early potential.
The vaccine segment's revenue grew by 1% (CER) to ￡9.55 billion, showing steady growth. Core product Shingrix (shingles vaccine) grew by 4%, benefiting from continued market penetration in the U.S. and expansion into new markets. The RSV vaccine Arexvy emerged as a new growth driver, with strong uptake, especially in the elderly population, though its growth was impacted by seasonal fluctuations. Meningitis and routine vaccines showed stable performance. The vaccine division's growth was driven by product lifecycle management and public health policies, though the segment faced challenges due to increasing competition and pricing pressures.
General medicines revenue declined by 3% (CER) to ￡5.22 billion, primarily due to generic competition and product portfolio optimization. Respiratory medicines like Trelegy and Ventolin showed stable demand, but older products like Seretide/Advair faced a decline. This decline reflects broader industry trends, but GSK mitigated the impact by focusing on high-value products like Trelegy. Overall, the division's performance highlighted GSK's successful strategy of shifting toward high-margin specialty medicines, with innovation as the core driver of growth.
Regionally, GSK achieved balanced growth in major global markets. Revenue in the U.S. grew by 3% (CER) to ￡16.86 billion, accounting for 52% of total group revenue. The growth was primarily driven by specialty medicines (such as HIV and oncology drugs) and vaccines (such as Arexvy), although pricing pressures from policy changes like the Inflation Reduction Act (IRA) were felt. The European market grew by 13% (CER) to ￡7.53 billion, benefiting from new drug launches (e.g., Exdensur approval in Europe) and increased public health investment. The international market, including Asia Pacific and emerging markets, grew by 12% (CER) to ￡8.28 billion, with significant contributions from China and Japan, especially in HIV medicines and vaccines.
The regional growth differences reflect market characteristics and product strategies: the U.S., as the largest market, showed steady growth but was impacted by regulatory pressures, while Europe and international markets benefited from the introduction of innovative products and improvements in healthcare infrastructure. Exchange rate fluctuations also had an impact on performance, with the British pound appreciating against both the U.S. dollar and the euro in 2025. At constant exchange rates, the growth was even more favorable. GSK's global footprint helps mitigate risks from dependence on any single market, although future performance may be influenced by geopolitical factors and exchange rate changes.
R&D continues to be the core engine of GSK's growth. In 2025, R&D spending totaled ￡6.25 billion, a 7% increase year-on-year. The company is focused on areas such as respiratory and immunology, oncology, and infectious diseases, with 79 projects in clinical development, including 17 in Phase III or regulatory stages.
In respiratory and immunology, camlipixant (a P2X3 receptor antagonist) for refractory chronic cough is undergoing Phase III trials (CALM-1 and CALM-2), with promising data expected. The ultra-long-acting IL-5 inhibitor Exdensur has been approved for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in the U.S. and Europe and is being expanded to COPD indications. The newly acquired efimosfermin (an FGF21 analog) for metabolic-related fatty liver disease (MASH) is undergoing Phase III trials (ZENITH) and holds significant potential.
In oncology, Blenrep (BCMA antibody-drug conjugate) shows advantages in multiple myeloma, with Phase III trials (DREAMM-7 and DREAMM-8) supporting its potential approval. Jemperli (PD-1 inhibitor) has made breakthroughs in endometrial and colorectal cancers, positioning it as a potential first-line therapy. The B7-H3 ADC drug risvutatug rezetecan has received breakthrough therapy designation from the FDA for small cell lung cancer.
In infectious diseases, bepirovirsen (HBV antisense oligonucleotide) achieved major endpoints in Phase III trials (B-Well 1 and B-Well 2) and may offer a functional cure for chronic hepatitis B, with registration expected in 2026. Antibiotics gepotidacin and tebipenem HBr are progressing well in treating resistant infections.
R&D successes, such as the supportive data for Exdensur and bepirovirsen in 2025, are expected to translate into commercial success. GSK is enhancing its pipeline through acquisitions (such as IDRx and BP Asset IX), aligning with its "Innovation Drives Growth" strategy. However, R&D comes with high risks and investments, and clinical trial results and regulatory approvals will be closely monitored.
On the legal front, GSK faces product liability and commercial lawsuits, but the risks in 2025 remain manageable. The Zantac (ranitidine) litigation has seen most cases resolved or dismissed, with 13 state court cases still ongoing, and an appeal in a multi-district litigation case. In the Avandia (rosiglitazone) case, a class certification for third-party payers was granted, and GSK has appealed. In commercial litigation, Tesaro and AnaptysBio have entered legal proceedings over Jemperli, but the impact is limited. As of the end of 2025, legal provisions were ￡210 million, down significantly from ￡1.446 billion in 2024, reflecting a reduction in litigation pressures. GSK has effectively managed risk through active defense and settlement strategies, with no major financial impact from legal issues.
GSK places a strong emphasis on shareholder returns. In 2025, the dividend per share was 66 pence, up from 61 pence in 2024, in line with its policy of distributing 40-60% of earnings as dividends. The fourth-quarter dividend increased to 18 pence, and the company expects a dividend of 70 pence per share in 2026. Additionally, GSK completed part of its ￡2 billion share buyback program, repurchasing 93 million shares (at a cost of ￡1.38 billion), which helped increase EPS. Capital allocation prioritizes investments in growth while balancing shareholder returns, reflecting strong financial discipline. By the end of 2025, basic EPS increased by 9%, and net assets rose to ￡15.96 billion, supporting sustainable returns.
Based on its 2025 performance, GSK has provided guidance for 2026: revenue growth of 3-5% (CER), core operating profit growth of 7-9%, and core EPS growth of 7-9%. The company's performance assumes double-digit growth in specialty medicines, with vaccines and general medicines remaining stable or experiencing slight declines. Looking further ahead, GSK targets a mid-to-high single-digit compound annual growth rate (CAGR) from 2021 to 2026 and anticipates revenue exceeding ￡40 billion by 2031, with a core operating margin above 30%. Growth will depend on pipeline products (such as bepirovirsen and camlipixant) and expansion into new markets. However, GSK must address generic competition (e.g., the expiration of the dolutegravir patent for HIV) and regulatory changes. The company's outlook relies on its innovative pipeline and strategic execution, assuming no major acquisitions or legal disruptions. The strong 2025 results lay the foundation for this path, but macroeconomic conditions, exchange rates, and public health events (such as pandemics) remain risks.
